Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. reports developments as a clinical-stage pharmaceutical company focused on pain and central nervous system therapeutics designed to reduce opioid abuse and overdose risk. Its recurring updates center on the TAAP™ (Trypsin-Activated Abuse Protection) prodrug platform, the MPAR® (Multi-Pill Abuse Resistance) overdose-protection platform, and product candidates including PF614 and PF614-MPAR.
Company news also covers clinical-study progress, FDA-related designations and regulatory engagement, peer-reviewed data, scientific conference presentations, intellectual-property updates, financing transactions, financial results, Nasdaq compliance matters, board and governance changes, and strategic-review disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Ensysce Biosciences, Inc. (NASDAQ:ENSC) announced that CEO Dr. Lynn Kirkpatrick will speak at a webinar titled ‘Strategies for Achieving Regulatory Milestones Faster’ on April 19, 2023, at 11:30 am ET. The webinar will highlight the integration of Quotient Sciences in developing PF614-MPAR, a novel opioid therapeutic for chronic pain designed to minimize abuse and overdose risks. Dr. Kirkpatrick will address the potential impact of MPAR on future pain management and share insights on Ensysce's collaboration with Quotient. Ensysce is committed to developing safer prescription drugs through innovative technologies like TAAP and MPAR, which are underpinned by substantial intellectual property protections.
Ensysce Biosciences, a clinical-stage biotech company focused on enhancing drug safety, announced the availability of an updated investor presentation on its website.
The company will host a corporate update conference call today, April 11, 2023, at 11:00 AM ET. Investors can dial in using the provided numbers and access a webcast link. A playback option will be available until May 9, 2023.
Ensysce employs proprietary technologies like TAAP and MPAR to develop tamper-proof medications aimed at reducing drug abuse risks.
Forward-looking statements indicate uncertainties in clinical success and regulatory approvals, emphasizing risks in ongoing trials and potential financial constraints.